EN | UA
EN | UA

Help Support

Back

Assessing the safety of standardized quality Tree Sublingual Immunotherapy Tablet

Assessing the safety of standardized quality Tree Sublingual Immunotherapy Tablet Assessing the safety of standardized quality Tree Sublingual Immunotherapy Tablet
Assessing the safety of standardized quality Tree Sublingual Immunotherapy Tablet Assessing the safety of standardized quality Tree Sublingual Immunotherapy Tablet

To estimate the tolerability and safety of European approved- standardised quality (SQ) tree sublingual immunotherapy (SLIT)-tablet (12 SQ-Bet) in people with allergic rhinitis and/or conjunctivitis.

See All

Key take away

As per this pooled analysis comprising of 471 individuals with allergic rhinitis and/or conjunctivitis, the safety profile of the recently approved standardised quality tree sublingual immunotherapy tablet supported its everyday, at-home sublingual administration once the first dose is tolerated when used under proper guidance of a physician.

Background

To estimate the tolerability and safety of European approved- standardised quality (SQ) tree sublingual immunotherapy (SLIT)-tablet (12 SQ-Bet) in people with allergic rhinitis and/or conjunctivitis.

Method

Safety data were pooled from 3 randomized controlled trials (2 phase-II and 1 phase-III) comprising of 471 adults and adolescents in the age group of 12 to 65 years with allergic rhinitis and/or conjunctivitis treated before and through one pollen season with 12 SQ-Bet taken one time per day. The placebo group had 458 individuals.

Result

With the use of 12 SQ-Bet, 39% patients reported having oral pruritis and 29% as having throat irritation deemed as the most commonly described investigational medicinal product (IMP)-linked adverse events (AEs). These were of mild or moderate severity, with majority of them resolving without any treatment and did not lead to treatment disturbance or withdrawal. Oral pruritus was more common among individuals with pollen food syndrome (PFS) (45%) as compared to without PFS (29%). Use of 12 SQ-Bet did not seem to provoke an increased asthma risk. 

Conclusion

12 SQ tree SLIT-tablet usage was regarded as well-tolerated in individuals with pollen allergies with no major AEs.

Source:

Allergy - European Journal of Allergy and Clinical Immunology

Article:

Safety of the SQ Tree Sublingual Immunotherapy Tablet: Pooled safety analysis of clinical trials

Authors:

Tilo Biedermann et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: